United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,311,581.28. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $547.87, for a total value of $5,478,700.00.
• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $565.63, for a total value of $5,656,300.00.
• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.94, for a total value of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total value of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total value of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $573.03, for a total value of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $578.58, for a total value of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $576.93, for a total value of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.61, for a total value of $5,726,100.00.

United Therapeutics Stock Up 0.4%

UTHR traded up $2.18 on Friday, hitting $549.87. The company had a trading volume of 652,923 shares, compared to its average volume of 480,820. The company has a market cap of $23.34 billion, a PE ratio of 20.30, a PEG ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The business’s fifty day simple moving average is $568.06 and its 200 day simple moving average is $518.61.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $6.63 EPS. On average, analysts anticipate that United Therapeutics Corporation will post 26.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of UTHR. Arjuna Capital grew its position in United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after buying an additional 18 shares during the period. Clearstead Advisors LLC grew its position in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares during the period. Sage Rhino Capital LLC grew its position in United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after buying an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC grew its position in United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after buying an additional 24 shares during the period. Finally, Meeder Advisory Services Inc. grew its position in United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after buying an additional 26 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on UTHR shares. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Bank of America boosted their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Finally, Cantor Fitzgerald boosted their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.